Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy DYN?
Source: SeekingAlpha
Analyst Upgrade: Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform, raising the price target from $11 to $40 per share, citing positive data expectations from Avidity Biosciences' late-stage trial.
Market Reaction: Following Novartis' $12 billion acquisition of Avidity, Dyne's shares surged over 40%, indicating strong market confidence in Dyne's potential upside.
Future Expectations: Analyst Kostas Biliouris anticipates nearly 50% upside for DYN, driven by the expected Phase 3 readout in H2 2026 for Avidity's RNA therapy targeting myotonic dystrophy type 1.
Upcoming Catalysts: Biliouris expects Dyne's DM1 program for z-basivarsen to succeed, with potential catalysts including an FDA review of the company's Duchenne muscular dystrophy candidate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.690
Low
17.00
Averages
39.33
High
60.00
Current: 17.690
Low
17.00
Averages
39.33
High
60.00
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Rise as NIO Reports Strong Earnings
- Quarterly Revenue Surge: NIO reported quarterly revenue of 34.65 billion yuan ($4.95 billion), reflecting a year-over-year increase of 75.9% and a sequential rise of 59.0%, surpassing the analyst consensus estimate of $4.61 billion, indicating robust market demand and sales growth potential.
- Significant Earnings Improvement: The company's adjusted earnings came in at 0.29 yuan (4 cents) per ADS, a remarkable turnaround from a loss of 3.17 yuan per ADS a year earlier, exceeding expectations for a 5-cent loss, showcasing effective cost control and enhanced profitability.
- Stock Price Rally: Following the earnings report, NIO shares surged 10.6% to $5.47, reflecting investor optimism regarding the company's future growth prospects and potentially attracting more institutional investor interest.
- Overall Market Performance: The U.S. stock market rose overall, with the Dow Jones index gaining around 200 points on Tuesday, indicating increased confidence in economic recovery, which may provide a favorable investment environment for NIO and other tech stocks.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Dyne Therapeutics Announces Major Clinical Updates on DMD and DM1 Trials
- Positive DELIVER Results: Dyne Therapeutics' DELIVER trial for DMD shows that z-rostudirsen (DYNE-251) leads to sustained improvements in cardiopulmonary function over 24 months, surpassing expected declines from natural history data, indicating its therapeutic potential across muscle systems including the heart and diaphragm.
- BLA Submission Plans: Dyne plans to submit a Biologics License Application (BLA) in Q2 2026, with a potential U.S. launch in Q1 2027, contingent on FDA priority review and approval, which could significantly enhance the company's market position.
- HARMONIA Trial Initiation: The company has initiated the Phase 3 HARMONIA trial for DM1 with z-basivarsen (DYNE-101), enrolling approximately 150 participants over 48 weeks, primarily assessing the 5x sit-to-stand test, aimed at supporting traditional approval in the U.S. and ex-U.S. markets.
- MDA Conference Presentation: Dyne will present new cardiopulmonary results and updates on the HARMONIA trial at the Muscular Dystrophy Association (MDA) conference on March 11, 2026, further enhancing its visibility and influence in the neuromuscular disease sector.
See More
Dyne Therapeutics Initiates Phase 3 HARMONIA Trial for DM1
- Trial Scale and Design: The HARMONIA Phase 3 trial will enroll approximately 150 participants aged 16 and older with myotonic dystrophy type 1 (DM1), utilizing a randomized, double-blind, placebo-controlled design aimed at assessing the multi-system efficacy, safety, and tolerability of z-basivarsen, which is expected to provide confirmatory data for traditional approval in the U.S.
- Primary Endpoint and Assessment Metrics: The primary endpoint is the change from baseline in the five times sit to stand (5xSTS) test at week 49, a reliable measure reflecting key areas of DM1 impairment, including lower extremity strength, balance, and trunk strength, which are critical for daily activities, alongside assessments of muscle function and CNS impact.
- FDA Alignment and Market Potential: Dyne Therapeutics has aligned with the FDA on the HARMONIA trial design, with results expected to support the conversion of z-basivarsen's Accelerated Approval to traditional approval in the U.S. and lay the groundwork for international marketing applications, indicating significant global market potential.
- Long-Term Extension Study: Following the 48-week double-blind placebo-controlled treatment period, patients will have the option to enter a 24-week long-term extension study where all participants will receive z-basivarsen, a design that not only aids in ongoing efficacy evaluation but may also enhance patient adherence and long-term health outcomes.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
U.S. Stocks Rise as NIO Reports Strong Earnings
- Quarterly Revenue Surge: NIO reported quarterly revenue of 34.65 billion yuan ($4.95 billion), reflecting a year-over-year increase of 75.9% and a sequential rise of 59.0%, surpassing the analyst consensus estimate of $4.61 billion, indicating robust market demand and sales growth potential.
- Significant Earnings Improvement: The company's adjusted earnings came in at 0.29 yuan (4 cents) per ADS, a remarkable turnaround from a loss of 3.17 yuan per ADS a year earlier, exceeding expectations for a 5-cent loss, showcasing effective cost control and enhanced profitability.
- Stock Price Rally: Following the earnings report, NIO shares surged 10.6% to $5.47, reflecting investor optimism regarding the company's future growth prospects and potentially attracting more institutional investor interest.
- Overall Market Performance: The U.S. stock market rose overall, with the Dow Jones index gaining around 200 points on Tuesday, indicating increased confidence in economic recovery, which may provide a favorable investment environment for NIO and other tech stocks.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Dyne Therapeutics Announces Major Clinical Updates on DMD and DM1 Trials
- Positive DELIVER Results: Dyne Therapeutics' DELIVER trial for DMD shows that z-rostudirsen (DYNE-251) leads to sustained improvements in cardiopulmonary function over 24 months, surpassing expected declines from natural history data, indicating its therapeutic potential across muscle systems including the heart and diaphragm.
- BLA Submission Plans: Dyne plans to submit a Biologics License Application (BLA) in Q2 2026, with a potential U.S. launch in Q1 2027, contingent on FDA priority review and approval, which could significantly enhance the company's market position.
- HARMONIA Trial Initiation: The company has initiated the Phase 3 HARMONIA trial for DM1 with z-basivarsen (DYNE-101), enrolling approximately 150 participants over 48 weeks, primarily assessing the 5x sit-to-stand test, aimed at supporting traditional approval in the U.S. and ex-U.S. markets.
- MDA Conference Presentation: Dyne will present new cardiopulmonary results and updates on the HARMONIA trial at the Muscular Dystrophy Association (MDA) conference on March 11, 2026, further enhancing its visibility and influence in the neuromuscular disease sector.
See More
Dyne Therapeutics Initiates Phase 3 HARMONIA Trial for DM1
- Trial Scale and Design: The HARMONIA Phase 3 trial will enroll approximately 150 participants aged 16 and older with myotonic dystrophy type 1 (DM1), utilizing a randomized, double-blind, placebo-controlled design aimed at assessing the multi-system efficacy, safety, and tolerability of z-basivarsen, which is expected to provide confirmatory data for traditional approval in the U.S.
- Primary Endpoint and Assessment Metrics: The primary endpoint is the change from baseline in the five times sit to stand (5xSTS) test at week 49, a reliable measure reflecting key areas of DM1 impairment, including lower extremity strength, balance, and trunk strength, which are critical for daily activities, alongside assessments of muscle function and CNS impact.
- FDA Alignment and Market Potential: Dyne Therapeutics has aligned with the FDA on the HARMONIA trial design, with results expected to support the conversion of z-basivarsen's Accelerated Approval to traditional approval in the U.S. and lay the groundwork for international marketing applications, indicating significant global market potential.
- Long-Term Extension Study: Following the 48-week double-blind placebo-controlled treatment period, patients will have the option to enter a 24-week long-term extension study where all participants will receive z-basivarsen, a design that not only aids in ongoing efficacy evaluation but may also enhance patient adherence and long-term health outcomes.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
